Merrimack Pharma's cancer drug wins FDA approval
Oct 22 (Reuters) - The U.S. Food and Drug Administration approved Merrimack Pharmaceutical Inc's pancreatic cancer therapy, Onivyde, making it the company's first approved drug.
Onivyde, when used in combination with chemotherapy drugs 5-fluorouracil (5-FU) and leucovorin, is intended to treat metastatic pancreatic cancer patients who have failed to respond to treatment with chemo drug gemcitabine. (http://1.usa.gov/1kvFKVt)
(Reporting By Samantha Kareen Nair in Bengaluru; Editing by Don Sebastian)